Programmed death-ligand 1 expression in tumor cells and tumor-infiltrating lymphocytes are associated with depth of tumor invasion in penile cancer

被引:2
|
作者
Sangkhamanon, Sakkarn [1 ]
Kotano, Natcha [1 ]
Sirithanaphol, Wichien [2 ]
Rompsaithong, Ukrit [2 ]
Kiatsopit, Pakorn [2 ]
Sookprasert, Aumkhae [3 ]
Wirasorn, Kosin [3 ]
Twinprai, Prin [4 ]
Watcharenwong, Piyakarn [3 ]
Chindaprasirt, Jarin [3 ,5 ]
机构
[1] Khon Kaen Univ, Fac Med, Dept Pathol, Khon Kaen 40002, Thailand
[2] Khon Kaen Univ, Fac Med, Dept Surg, Div Urol Surg, Khon Kaen 40002, Thailand
[3] Khon Kaen Univ, Fac Med, Dept Internal Med, Div Med Oncol, Khon Kaen 40002, Thailand
[4] Khon Kaen Univ, Fac Med, Dept Radiol, Khon Kaen 40002, Thailand
[5] Khon Kaen Univ, Fac Med, Dept Internal Med, Div Med Oncol, 123 Mitraparp Rd, Khon Kaen 40002, Thailand
关键词
penile cancer; PD-L1; programmed death-ligand 1; squamous cell carcinoma of penis; PD-L1; EXPRESSION;
D O I
10.3892/br.2023.1627
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The present study aimed to demonstrate the proportion of the programmed death-ligand 1 (PD-L1) expression in penile cancer patients and the association with clinicopathological parameters. Formalin-fixed paraffin-embedded specimens were obtained from 43 patients with primary penile squamous cell carcinoma treated at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, between 2008 and 2018. PD-L1 expression was evaluated by the immunohistochemistry using an SP263 monoclonal antibody. PD-L1 positivity was defined as >25% tumor cell staining or >25% tumor-associated immune cell staining. The correlation between PD-L1 expression and clinicopathological parameters was analyzed. A total of eight of 43 patients (18.6%) were identified as positive for PD-L1 expression in tumor cells and tumor-infiltrating lymphocytes. In the PD-L1 positive group, there was a significant association with pathological T stage (P=0.014) with a higher percentage of PD-L1 positive tumors in T1 stage compared with T2-T4 stage. In this cohort, there was a trend towards longer survival in patients with positive PD-L1 expression (5-year OS: 75% vs. 61.2%, P=0.19). Lymph node involvement and the location of tumor at the shaft of penis were two independent prognostic factors for survival. In conclusion, the PD-L1 expression was detected in 18% of penile cancer patients and high expression of PD-L1 was associated with the early T stage.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer
    Park, In Hae
    Kong, Sun-Young
    Ro, Jae Yoon
    Kwon, Youngmee
    Kang, Joo Hyun
    Mo, Hye Jin
    Jung, So-Youn
    Lee, Seeyoun
    Lee, Keun Seok
    Kang, Han-Sung
    Lee, Eunsook
    Joo, Jungnam
    Ro, Jungsil
    CLINICAL BREAST CANCER, 2016, 16 (01) : 51 - 58
  • [22] Expression of Programmed Death Receptor Ligand 1 with High Tumor Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer
    Bae, Sang Byung
    Cho, Hyun Deuk
    Oh, Mee-Hye
    Lee, Ji-Hye
    Jang, Si-Hyong
    Hong, Soon Auck
    Cho, Junhun
    Kim, Sung Yong
    Han, Sun Wook
    Lee, Jong Eun
    Kim, Han Jo
    Lee, Hyun Ju
    JOURNAL OF BREAST CANCER, 2016, 19 (03) : 242 - 251
  • [23] The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes
    Atilgan, Alev Ok
    Tepeoglu, Merih
    Ozen, Ozlem
    Reyhan, A. Nihan Haberal
    Ayhan, Ali
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2023, 65
  • [24] Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays
    Schwamborn, Kristina
    Ammann, Johannes U.
    Knuechel, Ruth
    Hartmann, Arndt
    Baretton, Gustavo
    Lasitschka, Felix
    Schirmacher, Peter
    Braunschweig, Till
    Tauber, Robert
    Erlmeier, Franziska
    Hieke-Schulz, Stefanie
    Weichert, Wilko
    VIRCHOWS ARCHIV, 2019, 475 (05) : 599 - 608
  • [25] Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer
    Yeh, Yi-Chen
    Ma, Hsiu-Hsun
    Chu, Ping-Yuan
    Ho, Hsiang-Ling
    Chou, Teh-Ying
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (07):
  • [26] Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays
    Kristina Schwamborn
    Johannes U Ammann
    Ruth Knüchel
    Arndt Hartmann
    Gustavo Baretton
    Felix Lasitschka
    Peter Schirmacher
    Till Braunschweig
    Robert Tauber
    Franziska Erlmeier
    Stefanie Hieke-Schulz
    Wilko Weichert
    Virchows Archiv, 2019, 475 : 599 - 608
  • [27] PROGRAMMED DEATH LIGAND 1 EXPRESSION AND TUMOR INFILTRATING LYMPHOCYTES IN TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1 AND 2
    Wang, Shiyang
    Liechty, Benjamin
    Patel, Seema
    Weber, Jeffrey
    Snuderl, Matija
    Karajannis, Matthias
    NEURO-ONCOLOGY, 2017, 19 : 31 - 31
  • [28] PROGRAMMED DEATH LIGAND 1 EXPRESSION AND TUMOR INFILTRATING LYMPHOCYTES IN TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1 AND 2
    Wang, Shiyang
    Liechty, Benjamin
    Patel, Seema
    Weber, Jeffrey
    Hollman, Travis
    Snuderl, Matija
    Karajannis, Matthias
    NEURO-ONCOLOGY, 2017, 19 : 216 - 216
  • [29] Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors
    Wang, Shiyang
    Liechty, Benjamin
    Patel, Seema
    Weber, Jeffrey S.
    Hollmann, Travis J.
    Snuderl, Matija
    Karajannis, Matthias A.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 138 (01) : 183 - 190
  • [30] Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors
    Shiyang Wang
    Benjamin Liechty
    Seema Patel
    Jeffrey S. Weber
    Travis J. Hollmann
    Matija Snuderl
    Matthias A. Karajannis
    Journal of Neuro-Oncology, 2018, 138 : 183 - 190